Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer

Osimertinib (Tagrisso, AstraZeneca) is indicated 'for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations'.

The dosage schedule is available in the summary of product characteristics.

The price is £5,770 for 80 mg and 40 mg osimertinib (pack of 30 tablets, excluding VAT; BNF online, accessed August 2020). The company has a commercial arrangement that makes osimertinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.